Drug Trial News

RSS

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

15 Sep 2011

Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer’s disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society. The symposium is being held in Yokohama, Japan from September 15-17, 2011.

15 Sep 2011

International patient groups anxiously await start of Huntington’s trial

Prana Biotechnology Limited received a very positive reaction from international patient groups and researchers at this week’s World Congress on Huntington’s Disease in Melbourne. The company had a major presence at the Congress and the Prana team has held numerous meetings and conversations with patient groups and researchers.

15 Sep 2011

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI's lead product candidate.

15 Sep 2011

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).

15 Sep 2011

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

While therapeutic advances have improved survival of patients with follicular lymphoma (FL), it remains an incurable disease with inevitable relapse. This underscores the need for therapies and strategies to extend the duration of remission without significantly increasing toxicity and while maintaining quality of life.

15 Sep 2011

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes.

From Novo Nordisk 15 Sep 2011

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured.

15 Sep 2011

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Alexion Pharmaceuticals, Inc. today announced that the Company's study of eculizumab in a small group of 14 patients with severe and refractory generalized myasthenia gravis, an ultra-rare and debilitating form of generalized myasthenia gravis (gMG), showed a strong disease improvement signal.

15 Sep 2011

First effective blood-stage vaccine against malaria

Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.

15 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Scientist granted over $138,000 to explore Vitamin C therapy in sepsis

Sepsis kills more people than breast, colorectal, pancreatic, and prostate cancers combined. Outside of coronary care units, it is the leading cause of mortality in intensive care units. Every year 18 million people worldwide develop this potentially fatal disease. Thanks to a generous grant of $138,238.65 from the Jesse and Julie Rasch Foundation, Lawson Health Research Institute's Dr. Michael Sharpe is exploring a new sepsis therapy using Vitamin C.

15 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.

14 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.

14 Sep 2011

Lexicon's LX4211 clinical data presented at EASD annual meeting

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

14 Sep 2011

Drug Trial News

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society

International patient groups anxiously await start of Huntington’s trial

KAI enters KAI-4169 development and commercialization agreement with Ono

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

First effective blood-stage vaccine against malaria

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

Scientist granted over $138,000 to explore Vitamin C therapy in sepsis

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Lexicon's LX4211 clinical data presented at EASD annual meeting

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News